Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol HCl / Contramid® Tablets to Twice Daily Tramadol HCl (SR) for the Treatment of Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or Females between the ages of 40 and 75 with a diagnosis of Osteoarthritis (OA) of the knee consistent with the American College of Rheumatology (ACR) Clinical Classification Criteria for Arthritis of the Knee (Altman, R. et al., 1986):~   * Knee pain at study enrolment,~  * Less than 30 minutes of morning stiffness with or without crepitus on active motion.~  * Confirmation either by arthroscopy or radiologist's report (X-rays showing osteophytes, joint space narrowing or subchondral bone sclerosis {eburnation}) within 1 year prior to entry into the study.~2. ESR \< 40 mm/h~3. Western Ontario and McMaster University Osteoarthritis Index (WOMAC) Pain Subscales total score equal to or more than 150 mm at baseline.~4. Oral and written language comprehension at a level sufficient to comply with the protocol and complete study-related materials.~5. The Patient signed and dated the (IEC) approved, written, informed consent prior to study participation~Exclusion Criteria:~1. Known rheumatoid arthritis or any other rheumatoid disease.~2. Secondary arthritis i.e. any of the following: septic arthritis; inflammatory joint disease; gout; pseudogout; Paget's disease; joint fracture; acromegaly; fibromyalgia; Wilson's disease; Ochronosis; Haemochromatosis; Osteochondromatosis; heritable arthritic disorders; or collagen gene mutations.~3. Obesity Class II \[body mass index (BMI) equal to or more than 35 kg/m2\] (NIH, 2000)~4. Major illness that required hospitalisation during the 3 months before commencement of the screening period.~5. Unwillingness to cease taking medication other than the study medication for arthritic pain, any other concomitant pain, or OA medications.~6. Patients who had previously failed tramadol HCl therapy or those who discontinued tramadol HCl due to AEs.~7. Patients who within the 3 weeks prior to study entry took the following medications: monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds (e.g. cyclobenzaprine, promethazine); neuroleptics; selective serotonin reuptake inhibitors; or other drugs which reduce seizure threshold.~8. Patients who took another investigational agent within the 30 days prior to study entry.~9. Patients with a history of seizure disorder other than Infantile Febrile Seizures.~10. Patients who were opioid dependent.~11. Patients with bowel disease causing malabsorption.~12. Patients who were pregnant or lactating or patients of child-bearing potential who were unwilling to utilise a medically approved method of contraception during participation in this clinical trial.~13. Patients with significant liver disease, defined as active hepatitis or elevated liver enzymes \>3 times the upper boundary of the normal range.~14. Patients with significant renal disease, defined as creatinine clearance \<30 mL/min as estimated by the method of Levey et al., 1999.~15. Current substance abuse or dependence, other than nicotine.~16. Allergy or adverse reaction to tramadol or any structurally similar drugs e.g. opiates.~17. Any other condition that, in the opinion of the investigators, adversely affected the patient's ability to complete the study or its measures.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 Tramadol HCl Contramid® Once A Day (Type: EXPERIMENTAL): None
- 2 Tramadol HCl Twice a day (SR) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).